New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: An appraisal

Claudio Borghi, Stefania Paolillo, Arrigo F.G. Cicero, Paola Gargiulo, Bruno Trimarco, Pasquale Perrone Filardi

Research output: Contribution to journalReview article

Abstract

Arterial hypertension (HTN) and atrial fibrillation often coexist and the combination of these two conditions carries an increased risk of stroke. HTN is one of the most important risk factors included in the scores for stoke prediction in atrial fibrillation used to assess the need of anticoagulation, and HTN has also been strictly related to bleeding complications of antithrombotic therapy. Antithrombotic drugs options include Vitamin K antagonists, or new oral anticoagulants, recently approved for stroke prevention in nonvalvular atrial fibrillation. More favorable new oral anticoagulant efficacy and safety, compared with warfarin, have been reported in hypertensive patients, making these drugs a first-line choice in this population to prevent cerebrovascular events and reduce the risk of major bleedings. The aim of this review is to explore the relationship among HTN, atrial fibrillation and the risk of stroke and to summarize the evidence on the impact of HTN on the choice of the most appropriate anticoagulation treatment.

Original languageEnglish
Pages (from-to)689-695
Number of pages7
JournalJournal of Hypertension
Volume35
Issue number4
DOIs
Publication statusPublished - Jan 1 2017

Keywords

  • Arterial hypertension
  • Atrial fibrillation
  • New oral anticoagulants
  • Stroke
  • Warfarin

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: An appraisal'. Together they form a unique fingerprint.

  • Cite this